DK2054434T3 - Myostatin antagonists - Google Patents

Info

Publication number

DK2054434T3

DK2054434T3 DK07834817.4T DK07834817T DK2054434T3 DK 2054434 T3 DK2054434 T3 DK 2054434T3 DK 07834817 T DK07834817 T DK 07834817T DK 2054434 T3 DK2054434 T3 DK 2054434T3

Authority

DK

Denmark

Prior art keywords

myostatin

muscle

polypeptide

amino acid

mice

Prior art date

2006-08-03

Links

• Espacenet
• Global Dossier
• Discuss

• 108010056852 Myostatin Proteins 0.000 title claims description 337
• 102000004472 Myostatin Human genes 0.000 title claims description 322
• 239000005557 antagonist Substances 0.000 title claims description 168
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 170
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 149
• 229920001184 polypeptide Polymers 0.000 claims description 132
• 210000003205 muscle Anatomy 0.000 claims description 107
• 230000000694 effects Effects 0.000 claims description 64
• 210000004027 cell Anatomy 0.000 claims description 54
• 150000001413 amino acids Chemical class 0.000 claims description 48
• 108090000623 proteins and genes Proteins 0.000 claims description 42
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
• 102000004169 proteins and genes Human genes 0.000 claims description 36
• 206010006895 Cachexia Diseases 0.000 claims description 26
• 238000001727 in vivo Methods 0.000 claims description 26
• 210000004899 c-terminal region Anatomy 0.000 claims description 25
• 201000000585 muscular atrophy Diseases 0.000 claims description 25
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
• 150000001875 compounds Chemical class 0.000 claims description 22
• 208000035475 disorder Diseases 0.000 claims description 22
• 102000040430 polynucleotide Human genes 0.000 claims description 22
• 108091033319 polynucleotide Proteins 0.000 claims description 22
• 239000002157 polynucleotide Substances 0.000 claims description 22
• 210000001519 tissue Anatomy 0.000 claims description 21
• 208000001076 sarcopenia Diseases 0.000 claims description 18
• 230000029663 wound healing Effects 0.000 claims description 18
• 230000000295 complement effect Effects 0.000 claims description 17
• 239000003814 drug Substances 0.000 claims description 16
• 230000006870 function Effects 0.000 claims description 15
• 206010028980 Neoplasm Diseases 0.000 claims description 14
• 208000008589 Obesity Diseases 0.000 claims description 13
• 206010012601 diabetes mellitus Diseases 0.000 claims description 13
• 235000020824 obesity Nutrition 0.000 claims description 13
• 201000011510 cancer Diseases 0.000 claims description 12
• 108020001507 fusion proteins Proteins 0.000 claims description 12
• 102000037865 fusion proteins Human genes 0.000 claims description 12
• 201000006938 muscular dystrophy Diseases 0.000 claims description 12
• 239000002773 nucleotide Substances 0.000 claims description 11
• 125000003729 nucleotide group Chemical group 0.000 claims description 11
• 230000001575 pathological effect Effects 0.000 claims description 10
• 239000008194 pharmaceutical composition Substances 0.000 claims description 9
• 238000000746 purification Methods 0.000 claims description 8
• 201000002481 Myositis Diseases 0.000 claims description 7
• 208000001132 Osteoporosis Diseases 0.000 claims description 7
• 150000002632 lipids Chemical class 0.000 claims description 7
• 206010019280 Heart failures Diseases 0.000 claims description 6
• 206010019663 Hepatic failure Diseases 0.000 claims description 6
• 208000001647 Renal Insufficiency Diseases 0.000 claims description 6
• 208000022531 anorexia Diseases 0.000 claims description 6
• 239000003795 chemical substances by application Substances 0.000 claims description 6
• 206010061428 decreased appetite Diseases 0.000 claims description 6
• 230000004927 fusion Effects 0.000 claims description 6
• 208000017169 kidney disease Diseases 0.000 claims description 6
• 201000006370 kidney failure Diseases 0.000 claims description 6
• 208000019423 liver disease Diseases 0.000 claims description 6
• 208000007903 liver failure Diseases 0.000 claims description 6
• 231100000835 liver failure Toxicity 0.000 claims description 6
• 208000005264 motor neuron disease Diseases 0.000 claims description 6
• 230000001225 therapeutic effect Effects 0.000 claims description 6
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
• 206010028311 Muscle hypertrophy Diseases 0.000 claims description 5
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 230000012042 muscle hypertrophy Effects 0.000 claims description 5
• 108060003951 Immunoglobulin Proteins 0.000 claims description 4
• 102000018358 immunoglobulin Human genes 0.000 claims description 4
• 230000036961 partial effect Effects 0.000 claims description 4
• 125000000539 amino acid group Chemical group 0.000 claims description 3
• 238000009826 distribution Methods 0.000 claims description 3
• 150000008574 D-amino acids Chemical class 0.000 claims description 2
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 2
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 2
• 230000004807 localization Effects 0.000 claims description 2
• 229920002704 polyhistidine Polymers 0.000 claims description 2
• 206010028643 Myopathy endocrine Diseases 0.000 claims 1
• 238000011260 co-administration Methods 0.000 claims 1
• 230000009918 complex formation Effects 0.000 claims 1
• 208000018360 neuromuscular disease Diseases 0.000 claims 1
• 208000027232 peripheral nervous system disease Diseases 0.000 claims 1
• 241000699670 Mus sp. Species 0.000 description 100
• 210000003098 myoblast Anatomy 0.000 description 74
• 238000011282 treatment Methods 0.000 description 68
• 210000001057 smooth muscle myoblast Anatomy 0.000 description 55
• 235000001014 amino acid Nutrition 0.000 description 52
• 230000001965 increasing effect Effects 0.000 description 52
• 238000000034 method Methods 0.000 description 43
• 229940024606 amino acid Drugs 0.000 description 40
• 235000018102 proteins Nutrition 0.000 description 32
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
• 230000014509 gene expression Effects 0.000 description 29
• 230000035755 proliferation Effects 0.000 description 29
• 208000027418 Wounds and injury Diseases 0.000 description 28
• 210000002540 macrophage Anatomy 0.000 description 28
• 239000011780 sodium chloride Substances 0.000 description 28
• 230000020411 cell activation Effects 0.000 description 27
• 241000282414 Homo sapiens Species 0.000 description 25
• 206010028289 Muscle atrophy Diseases 0.000 description 25
• 101100351033 Mus musculus Pax7 gene Proteins 0.000 description 23
• 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 23
• 230000037396 body weight Effects 0.000 description 21
• 229960003957 dexamethasone Drugs 0.000 description 21
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 21
• 208000014674 injury Diseases 0.000 description 21
• 230000009756 muscle regeneration Effects 0.000 description 20
• 230000006378 damage Effects 0.000 description 19
• 210000000577 adipose tissue Anatomy 0.000 description 18
• 230000005012 migration Effects 0.000 description 17
• 238000013508 migration Methods 0.000 description 17
• 241001465754 Metazoa Species 0.000 description 16
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 16
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 15
• 201000010099 disease Diseases 0.000 description 15
• 239000012528 membrane Substances 0.000 description 13
• 238000006467 substitution reaction Methods 0.000 description 13
• 241000699666 Mus <mouse, genus> Species 0.000 description 12
• 206010052428 Wound Diseases 0.000 description 12
• 230000003247 decreasing effect Effects 0.000 description 12
• 210000004379 membrane Anatomy 0.000 description 12
• 108020004999 messenger RNA Proteins 0.000 description 12
• 230000037257 muscle growth Effects 0.000 description 12
• 102000004420 Creatine Kinase Human genes 0.000 description 11
• 108010042126 Creatine kinase Proteins 0.000 description 11
• 108050006400 Cyclin Proteins 0.000 description 11
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 11
• 108091034117 Oligonucleotide Proteins 0.000 description 11
• 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 11
• 230000009286 beneficial effect Effects 0.000 description 11
• 239000000203 mixture Substances 0.000 description 11
• 230000008929 regeneration Effects 0.000 description 11
• 238000011069 regeneration method Methods 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 10
• 230000007423 decrease Effects 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 230000022379 skeletal muscle tissue development Effects 0.000 description 10
• 108010035532 Collagen Proteins 0.000 description 9
• 102000008186 Collagen Human genes 0.000 description 9
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 230000004071 biological effect Effects 0.000 description 9
• 229920001436 collagen Polymers 0.000 description 9
• 230000004069 differentiation Effects 0.000 description 9
• 239000000835 fiber Substances 0.000 description 9
• -1 for example Proteins 0.000 description 9
• 238000000338 in vitro Methods 0.000 description 9
• 239000003112 inhibitor Substances 0.000 description 9
• 230000002401 inhibitory effect Effects 0.000 description 9
• 230000004220 muscle function Effects 0.000 description 9
• 210000004940 nucleus Anatomy 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 230000008685 targeting Effects 0.000 description 9
• 230000003827 upregulation Effects 0.000 description 9
• QCLHLXDWRKOHRR-GUBZILKMSA-N Asp-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N QCLHLXDWRKOHRR-GUBZILKMSA-N 0.000 description 8
• 241000283690 Bos taurus Species 0.000 description 8
• 108010090461 DFG peptide Proteins 0.000 description 8
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
• 208000021642 Muscular disease Diseases 0.000 description 8
• 201000009623 Myopathy Diseases 0.000 description 8
• KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 8
• 230000008485 antagonism Effects 0.000 description 8
• 239000002975 chemoattractant Substances 0.000 description 8
• 235000018417 cysteine Nutrition 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 238000000151 deposition Methods 0.000 description 8
• 230000008021 deposition Effects 0.000 description 8
• 239000012634 fragment Substances 0.000 description 8
• 108010018006 histidylserine Proteins 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 238000010172 mouse model Methods 0.000 description 8
• 230000020763 muscle atrophy Effects 0.000 description 8
• 150000007523 nucleic acids Chemical class 0.000 description 8
• 229920000642 polymer Polymers 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 210000002027 skeletal muscle Anatomy 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
• QJHOOKBAHRJPPX-QWRGUYRKSA-N Asp-Phe-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 QJHOOKBAHRJPPX-QWRGUYRKSA-N 0.000 description 7
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 7
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
• 241000124008 Mammalia Species 0.000 description 7
• 208000029549 Muscle injury Diseases 0.000 description 7
• 230000002159 abnormal effect Effects 0.000 description 7
• 238000007792 addition Methods 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 230000004048 modification Effects 0.000 description 7
• 238000012986 modification Methods 0.000 description 7
• 230000012107 myoblast migration Effects 0.000 description 7
• 230000001114 myogenic effect Effects 0.000 description 7
• 230000002035 prolonged effect Effects 0.000 description 7
• 238000011084 recovery Methods 0.000 description 7
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
• 241000283073 Equus caballus Species 0.000 description 6
• 102000016970 Follistatin Human genes 0.000 description 6
• 108010014612 Follistatin Proteins 0.000 description 6
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
• FGNQZXKVAZIMCI-CIUDSAMLSA-N Leu-Asp-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N FGNQZXKVAZIMCI-CIUDSAMLSA-N 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• JJKSSJVYOVRJMZ-FXQIFTODSA-N Ser-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)CN=C(N)N JJKSSJVYOVRJMZ-FXQIFTODSA-N 0.000 description 6
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 230000003042 antagnostic effect Effects 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 230000027455 binding Effects 0.000 description 6
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 239000003862 glucocorticoid Substances 0.000 description 6
• 230000001976 improved effect Effects 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 210000003141 lower extremity Anatomy 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 102000039446 nucleic acids Human genes 0.000 description 6
• 108020004707 nucleic acids Proteins 0.000 description 6
• 230000007170 pathology Effects 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 230000003389 potentiating effect Effects 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 238000012384 transportation and delivery Methods 0.000 description 6
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 206010016654 Fibrosis Diseases 0.000 description 5
• 206010020880 Hypertrophy Diseases 0.000 description 5
• 230000005856 abnormality Effects 0.000 description 5
• 238000009825 accumulation Methods 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 238000001516 cell proliferation assay Methods 0.000 description 5
• 230000035605 chemotaxis Effects 0.000 description 5
• 108010004073 cysteinylcysteine Proteins 0.000 description 5
• 230000002124 endocrine Effects 0.000 description 5
• 230000002708 enhancing effect Effects 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 230000004761 fibrosis Effects 0.000 description 5
• 125000000524 functional group Chemical group 0.000 description 5
• 239000003102 growth factor Substances 0.000 description 5
• 230000006872 improvement Effects 0.000 description 5
• 238000003780 insertion Methods 0.000 description 5
• 230000037431 insertion Effects 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 230000002503 metabolic effect Effects 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 230000001338 necrotic effect Effects 0.000 description 5
• 210000000715 neuromuscular junction Anatomy 0.000 description 5
• 210000000578 peripheral nerve Anatomy 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 239000002243 precursor Substances 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 230000001172 regenerating effect Effects 0.000 description 5
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 5
• 230000003835 satellite cell maintenance involved in skeletal muscle regeneration Effects 0.000 description 5
• 208000002320 spinal muscular atrophy Diseases 0.000 description 5
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
• 230000008733 trauma Effects 0.000 description 5
• 108010059616 Activins Proteins 0.000 description 4
• 102000005606 Activins Human genes 0.000 description 4
• DHBKYZYFEXXUAK-ONGXEEELSA-N Ala-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 DHBKYZYFEXXUAK-ONGXEEELSA-N 0.000 description 4
• QCTOLCVIGRLMQS-HRCADAONSA-N Arg-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O QCTOLCVIGRLMQS-HRCADAONSA-N 0.000 description 4
• GWIJZUVQVDJHDI-AVGNSLFASA-N Asp-Phe-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O GWIJZUVQVDJHDI-AVGNSLFASA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 4
• 241000287828 Gallus gallus Species 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
• AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 4
• MPOHDJKRBLVGCT-CIUDSAMLSA-N Lys-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N MPOHDJKRBLVGCT-CIUDSAMLSA-N 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
• ZAGPDPNPWYPEIR-SRVKXCTJSA-N Tyr-Cys-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O ZAGPDPNPWYPEIR-SRVKXCTJSA-N 0.000 description 4
• 239000000488 activin Substances 0.000 description 4
• 235000003704 aspartic acid Nutrition 0.000 description 4
• 108010069205 aspartyl-phenylalanine Proteins 0.000 description 4
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 210000000988 bone and bone Anatomy 0.000 description 4
• 238000013270 controlled release Methods 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 235000013922 glutamic acid Nutrition 0.000 description 4
• 239000004220 glutamic acid Substances 0.000 description 4
• 108010049041 glutamylalanine Proteins 0.000 description 4
• 229960002591 hydroxyproline Drugs 0.000 description 4
• 206010020718 hyperplasia Diseases 0.000 description 4
• 210000001161 mammalian embryo Anatomy 0.000 description 4
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
• 229920000139 polyethylene terephthalate Polymers 0.000 description 4
• 239000005020 polyethylene terephthalate Substances 0.000 description 4
• 239000013641 positive control Substances 0.000 description 4
• 230000001737 promoting effect Effects 0.000 description 4
• 230000008439 repair process Effects 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• 229940037128 systemic glucocorticoids Drugs 0.000 description 4
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
• 230000014616 translation Effects 0.000 description 4
• 239000004474 valine Substances 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• CWFMWBHMIMNZLN-NAKRPEOUSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CWFMWBHMIMNZLN-NAKRPEOUSA-N 0.000 description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
• 102000006822 Agouti Signaling Protein Human genes 0.000 description 3
• 108010072151 Agouti Signaling Protein Proteins 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
• 101000886576 Bos taurus Growth/differentiation factor 8 Proteins 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 241000484025 Cuniculus Species 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 3
• 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 3
• 102000004877 Insulin Human genes 0.000 description 3
• 108090001061 Insulin Proteins 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• 102400000401 Latency-associated peptide Human genes 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• GGAPIOORBXHMNY-ULQDDVLXSA-N Lys-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)O GGAPIOORBXHMNY-ULQDDVLXSA-N 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 3
• 206010028851 Necrosis Diseases 0.000 description 3
• 108700026244 Open Reading Frames Proteins 0.000 description 3
• 241000288049 Perdix perdix Species 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• 102100021947 Survival motor neuron protein Human genes 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• BIWVVOHTKDLRMP-ULQDDVLXSA-N Tyr-Pro-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BIWVVOHTKDLRMP-ULQDDVLXSA-N 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 235000009582 asparagine Nutrition 0.000 description 3
• 229960001230 asparagine Drugs 0.000 description 3
• 230000004888 barrier function Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 210000004413 cardiac myocyte Anatomy 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 230000001276 controlling effect Effects 0.000 description 3
• 239000012894 fetal calf serum Substances 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 108010084389 glycyltryptophan Proteins 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 230000035876 healing Effects 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 230000028709 inflammatory response Effects 0.000 description 3
• 229910052500 inorganic mineral Inorganic materials 0.000 description 3
• 229940125396 insulin Drugs 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 108010082117 matrigel Proteins 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 238000010232 migration assay Methods 0.000 description 3
• 230000001617 migratory effect Effects 0.000 description 3
• 239000011707 mineral Substances 0.000 description 3
• 210000004165 myocardium Anatomy 0.000 description 3
• 210000001087 myotubule Anatomy 0.000 description 3
• 230000017074 necrotic cell death Effects 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 238000007390 skin biopsy Methods 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 108010051110 tyrosyl-lysine Proteins 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• 241000628470 Aclees Species 0.000 description 2
• 208000002016 Adenosine monophosphate deaminase deficiency Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 2
• KACWACLNYLSVCA-VHWLVUOQSA-N Asp-Trp-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KACWACLNYLSVCA-VHWLVUOQSA-N 0.000 description 2
• 201000006935 Becker muscular dystrophy Diseases 0.000 description 2
• 229940122361 Bisphosphonate Drugs 0.000 description 2
• 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 206010058892 Carnitine deficiency Diseases 0.000 description 2
• 206010050215 Carnitine palmitoyltransferase deficiency Diseases 0.000 description 2
• 208000015374 Central core disease Diseases 0.000 description 2
• 241000282994 Cervidae Species 0.000 description 2
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 102000029816 Collagenase Human genes 0.000 description 2
• 108060005980 Collagenase Proteins 0.000 description 2
• 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 description 2
• GSNRZJNHMVMOFV-ACZMJKKPSA-N Cys-Asp-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N GSNRZJNHMVMOFV-ACZMJKKPSA-N 0.000 description 2
• 102100034239 Emerin Human genes 0.000 description 2
• 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 2
• 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• 208000024412 Friedreich ataxia Diseases 0.000 description 2
• 102100035233 Furin Human genes 0.000 description 2
• 108090001126 Furin Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 229940122459 Glutamate antagonist Drugs 0.000 description 2
• BIRKKBCSAIHDDF-WDSKDSINSA-N Gly-Glu-Cys Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O BIRKKBCSAIHDDF-WDSKDSINSA-N 0.000 description 2
• YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 206010053185 Glycogen storage disease type II Diseases 0.000 description 2
• 108010051696 Growth Hormone Proteins 0.000 description 2
• 206010053759 Growth retardation Diseases 0.000 description 2
• ILUVWFTXAUYOBW-CUJWVEQBSA-N His-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)N)O ILUVWFTXAUYOBW-CUJWVEQBSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101001092185 Homo sapiens Regulator of cell cycle RGCC Proteins 0.000 description 2
• 101000597193 Homo sapiens Telethonin Proteins 0.000 description 2
• 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 2
• 208000027747 Kennedy disease Diseases 0.000 description 2
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• 108700006394 Lactate Dehydrogenase Deficiency Proteins 0.000 description 2
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
• 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 2
• 108090001090 Lectins Proteins 0.000 description 2
• 102000004856 Lectins Human genes 0.000 description 2
• 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 2
• 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 2
• 208000010316 Myotonia congenita Diseases 0.000 description 2
• 208000012905 Myotonic disease Diseases 0.000 description 2
• 208000034965 Nemaline Myopathies Diseases 0.000 description 2
• 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 241000009328 Perro Species 0.000 description 2
• MGBRZXXGQBAULP-DRZSPHRISA-N Phe-Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 MGBRZXXGQBAULP-DRZSPHRISA-N 0.000 description 2
• OVJMCXAPGFDGMG-HKUYNNGSSA-N Phe-Gly-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O OVJMCXAPGFDGMG-HKUYNNGSSA-N 0.000 description 2
• VDTYRPWRWRCROL-UFYCRDLUSA-N Phe-Val-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 VDTYRPWRWRCROL-UFYCRDLUSA-N 0.000 description 2
• 108700010203 Phosphoglycerate Kinase 1 Deficiency Proteins 0.000 description 2
• 101710118538 Protease Proteins 0.000 description 2
• 229940123924 Protein kinase C inhibitor Drugs 0.000 description 2
• 208000033522 Proximal spinal muscular atrophy type 2 Diseases 0.000 description 2
• 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 102100035542 Regulator of cell cycle RGCC Human genes 0.000 description 2
• 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 2
• 208000020221 Short stature Diseases 0.000 description 2
• 102100038803 Somatotropin Human genes 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• 102100035155 Telethonin Human genes 0.000 description 2
• 208000035954 Thomsen and Becker disease Diseases 0.000 description 2
• GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 2
• FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 2
• 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 2
• DEZKIRSBKKXUEV-NYVOZVTQSA-N Trp-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N DEZKIRSBKKXUEV-NYVOZVTQSA-N 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 229920000392 Zymosan Polymers 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 230000000996 additive effect Effects 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 239000002160 alpha blocker Substances 0.000 description 2
• 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 2
• 239000003194 amino acid receptor blocking agent Substances 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 239000002220 antihypertensive agent Substances 0.000 description 2
• 229940030600 antihypertensive agent Drugs 0.000 description 2
• 230000003305 autocrine Effects 0.000 description 2
• 235000019445 benzyl alcohol Nutrition 0.000 description 2
• 235000021028 berry Nutrition 0.000 description 2
• 239000002876 beta blocker Substances 0.000 description 2
• 229940097320 beta blocking agent Drugs 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 230000031018 biological processes and functions Effects 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 150000004663 bisphosphonates Chemical class 0.000 description 2
• 230000008468 bone growth Effects 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 125000002843 carboxylic acid group Chemical group 0.000 description 2
• 230000001925 catabolic effect Effects 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000006369 cell cycle progression Effects 0.000 description 2
• 230000011712 cell development Effects 0.000 description 2
• 201000007303 central core myopathy Diseases 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 230000001513 chemoinhibitory effect Effects 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229960002424 collagenase Drugs 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 201000006815 congenital muscular dystrophy Diseases 0.000 description 2
• 229940111134 coxibs Drugs 0.000 description 2
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000002939 deleterious effect Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 201000009338 distal myopathy Diseases 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 238000003366 endpoint assay Methods 0.000 description 2
• 239000000262 estrogen Substances 0.000 description 2
• 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 2
• 201000004502 glycogen storage disease II Diseases 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 239000000122 growth hormone Substances 0.000 description 2
• 231100000001 growth retardation Toxicity 0.000 description 2
• 239000000710 homodimer Substances 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 201000008319 inclusion body myositis Diseases 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 201000006913 intermediate spinal muscular atrophy Diseases 0.000 description 2
• QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
• 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 239000002523 lectin Substances 0.000 description 2
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
• 229960000907 methylthioninium chloride Drugs 0.000 description 2
• 210000000663 muscle cell Anatomy 0.000 description 2
• 238000002703 mutagenesis Methods 0.000 description 2
• 231100000350 mutagenesis Toxicity 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 239000005022 packaging material Substances 0.000 description 2
• 208000027838 paramyotonia congenita of Von Eulenburg Diseases 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 208000029308 periodic paralysis Diseases 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 108010073101 phenylalanylleucine Proteins 0.000 description 2
• 239000002504 physiological saline solution Substances 0.000 description 2
• 244000144977 poultry Species 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 239000003881 protein kinase C inhibitor Substances 0.000 description 2
• 238000001243 protein synthesis Methods 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 231100000075 skin burn Toxicity 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 230000037317 transdermal delivery Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 208000032521 type II spinal muscular atrophy Diseases 0.000 description 2
• 208000016261 weight loss Diseases 0.000 description 2
• WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
• UTVXFQMLZSPQLB-DHVFOXMCSA-N (3s,4r,5s,6s)-2-amino-6-methyloxane-3,4,5-triol Chemical group C[C@@H]1OC(N)[C@@H](O)[C@H](O)[C@@H]1O UTVXFQMLZSPQLB-DHVFOXMCSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• BBYWOYAFBUOUFP-JOCHJYFZSA-N 1-stearoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCCN BBYWOYAFBUOUFP-JOCHJYFZSA-N 0.000 description 1
• FMKLAIBZMCURLI-BFVRRIQPSA-N 15-Keto-13,14-dihydroprostaglandin A2 Chemical compound CCCCCC(=O)CC[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O FMKLAIBZMCURLI-BFVRRIQPSA-N 0.000 description 1
• MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• 102100032123 AMP deaminase 1 Human genes 0.000 description 1
• 102100032922 ATP-dependent 6-phosphofructokinase, muscle type Human genes 0.000 description 1
• 108091005508 Acid proteases Proteins 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• XCVRVWZTXPCYJT-BIIVOSGPSA-N Ala-Asn-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N XCVRVWZTXPCYJT-BIIVOSGPSA-N 0.000 description 1
• HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 1
• VQAVBBCZFQAAED-FXQIFTODSA-N Ala-Pro-Asn Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)O)N VQAVBBCZFQAAED-FXQIFTODSA-N 0.000 description 1
• BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 1
• OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 1
• OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 1
• KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 1
• OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 1
• 239000012103 Alexa Fluor 488 Substances 0.000 description 1
• ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Substances [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• NTAZNGWBXRVEDJ-FXQIFTODSA-N Arg-Asp-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NTAZNGWBXRVEDJ-FXQIFTODSA-N 0.000 description 1
• TTXYKSADPSNOIF-IHRRRGAJSA-N Arg-Asp-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O TTXYKSADPSNOIF-IHRRRGAJSA-N 0.000 description 1
• OSASDIVHOSJVII-WDSKDSINSA-N Arg-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N OSASDIVHOSJVII-WDSKDSINSA-N 0.000 description 1
• AHPWQERCDZTTNB-FXQIFTODSA-N Arg-Cys-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N AHPWQERCDZTTNB-FXQIFTODSA-N 0.000 description 1
• WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
• GFMWTFHOZGLTLC-AVGNSLFASA-N Arg-His-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCSC)C(O)=O GFMWTFHOZGLTLC-AVGNSLFASA-N 0.000 description 1
• CVXXSWQORBZAAA-SRVKXCTJSA-N Arg-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N CVXXSWQORBZAAA-SRVKXCTJSA-N 0.000 description 1
• VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 1
• KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 1
• SJUXYGVRSGTPMC-IMJSIDKUSA-N Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O SJUXYGVRSGTPMC-IMJSIDKUSA-N 0.000 description 1
• WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 1
• RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 1
• NLDNNZKUSLAYFW-NHCYSSNCSA-N Asn-Lys-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NLDNNZKUSLAYFW-NHCYSSNCSA-N 0.000 description 1
• GZXOUBTUAUAVHD-ACZMJKKPSA-N Asn-Ser-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GZXOUBTUAUAVHD-ACZMJKKPSA-N 0.000 description 1
• VBKIFHUVGLOJKT-FKZODXBYSA-N Asn-Thr Chemical compound C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)N)O VBKIFHUVGLOJKT-FKZODXBYSA-N 0.000 description 1
• RDLYUKRPEJERMM-XIRDDKMYSA-N Asn-Trp-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O RDLYUKRPEJERMM-XIRDDKMYSA-N 0.000 description 1
• MJKBOVWWADWLHV-ZLUOBGJFSA-N Asp-Cys-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)C(=O)O MJKBOVWWADWLHV-ZLUOBGJFSA-N 0.000 description 1
• XJQRWGXKUSDEFI-ACZMJKKPSA-N Asp-Glu-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O XJQRWGXKUSDEFI-ACZMJKKPSA-N 0.000 description 1
• QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 1
• ZARXTZFGQZBYFO-JQWIXIFHSA-N Asp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(O)=O)N)C(O)=O)=CNC2=C1 ZARXTZFGQZBYFO-JQWIXIFHSA-N 0.000 description 1
• ZQFZEBRNAMXXJV-KKUMJFAQSA-N Asp-Tyr-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O ZQFZEBRNAMXXJV-KKUMJFAQSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
• 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
• 108010029692 Bisphosphoglycerate mutase Proteins 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 208000031648 Body Weight Changes Diseases 0.000 description 1
• 208000010392 Bone Fractures Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 201000003728 Centronuclear myopathy Diseases 0.000 description 1
• 108010011008 Chalones Proteins 0.000 description 1
• 201000006868 Charcot-Marie-Tooth disease type 3 Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• RGTVXXNMOGHRAY-WDSKDSINSA-N Cys-Arg Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RGTVXXNMOGHRAY-WDSKDSINSA-N 0.000 description 1
• BUXAPSQPMALTOY-WHFBIAKZSA-N Cys-Glu Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BUXAPSQPMALTOY-WHFBIAKZSA-N 0.000 description 1
• FANFRJOFTYCNRG-JYBASQMISA-N Cys-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CS)N)O FANFRJOFTYCNRG-JYBASQMISA-N 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 101100228739 Danio rerio mstnb gene Proteins 0.000 description 1
• 108700043208 Dimauro disease Proteins 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 101710202200 Endolysin A Proteins 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 241000701533 Escherichia virus T4 Species 0.000 description 1
• 206010063560 Excessive granulation tissue Diseases 0.000 description 1
• 208000036119 Frailty Diseases 0.000 description 1
• 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
• 108010027920 GTPase-Activating Proteins Proteins 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 description 1
• CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 1
• YLJHCWNDBKKOEB-IHRRRGAJSA-N Glu-Glu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YLJHCWNDBKKOEB-IHRRRGAJSA-N 0.000 description 1
• BCYGDJXHAGZNPQ-DCAQKATOSA-N Glu-Lys-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O BCYGDJXHAGZNPQ-DCAQKATOSA-N 0.000 description 1
• KXTAGESXNQEZKB-DZKIICNBSA-N Glu-Phe-Val Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 KXTAGESXNQEZKB-DZKIICNBSA-N 0.000 description 1
• VAXIVIPMCTYSHI-YUMQZZPRSA-N Gly-His-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN VAXIVIPMCTYSHI-YUMQZZPRSA-N 0.000 description 1
• GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
• PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 1
• QSQXZZCGPXQBPP-BQBZGAKWSA-N Gly-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)CN)C(=O)N[C@@H](CS)C(=O)O QSQXZZCGPXQBPP-BQBZGAKWSA-N 0.000 description 1
• WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
• JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 1
• 102100029492 Glycogen phosphorylase, muscle form Human genes 0.000 description 1
• 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
• HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 1
• LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 1
• STOOMQFEJUVAKR-KKUMJFAQSA-N His-His-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CNC=N1 STOOMQFEJUVAKR-KKUMJFAQSA-N 0.000 description 1
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
• VIJMRAIWYWRXSR-CIUDSAMLSA-N His-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 VIJMRAIWYWRXSR-CIUDSAMLSA-N 0.000 description 1
• IXQGOKWTQPCIQM-YJRXYDGGSA-N His-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O IXQGOKWTQPCIQM-YJRXYDGGSA-N 0.000 description 1
• 101000730838 Homo sapiens ATP-dependent 6-phosphofructokinase, muscle type Proteins 0.000 description 1
• 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
• 101000700475 Homo sapiens Glycogen phosphorylase, muscle form Proteins 0.000 description 1
• 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
• 101100351819 Homo sapiens PGAM2 gene Proteins 0.000 description 1
• 101000650854 Homo sapiens Small glutamine-rich tetratricopeptide repeat-containing protein alpha Proteins 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• MTFVYKQRLXYAQN-LAEOZQHASA-N Ile-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O MTFVYKQRLXYAQN-LAEOZQHASA-N 0.000 description 1
• KBAPKNDWAGVGTH-IGISWZIWSA-N Ile-Ile-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KBAPKNDWAGVGTH-IGISWZIWSA-N 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
• 150000008575 L-amino acids Chemical class 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 101800001155 Latency-associated peptide Proteins 0.000 description 1
• HASRFYOMVPJRPU-SRVKXCTJSA-N Leu-Arg-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HASRFYOMVPJRPU-SRVKXCTJSA-N 0.000 description 1
• KKXDHFKZWKLYGB-GUBZILKMSA-N Leu-Asn-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKXDHFKZWKLYGB-GUBZILKMSA-N 0.000 description 1
• HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 1
• ZFNLIDNJUWNIJL-WDCWCFNPSA-N Leu-Glu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZFNLIDNJUWNIJL-WDCWCFNPSA-N 0.000 description 1
• KOSWSHVQIVTVQF-ZPFDUUQYSA-N Leu-Ile-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O KOSWSHVQIVTVQF-ZPFDUUQYSA-N 0.000 description 1
• YRRCOJOXAJNSAX-IHRRRGAJSA-N Leu-Pro-Lys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N YRRCOJOXAJNSAX-IHRRRGAJSA-N 0.000 description 1
• AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 1
• BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 description 1
• LMDVGHQPPPLYAR-IHRRRGAJSA-N Leu-Val-His Chemical compound N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O LMDVGHQPPPLYAR-IHRRRGAJSA-N 0.000 description 1
• 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
• KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
• AAORVPFVUIHEAB-YUMQZZPRSA-N Lys-Asp-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O AAORVPFVUIHEAB-YUMQZZPRSA-N 0.000 description 1
• ZXEUFAVXODIPHC-GUBZILKMSA-N Lys-Glu-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZXEUFAVXODIPHC-GUBZILKMSA-N 0.000 description 1
• ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 description 1
• JYVCOTWSRGFABJ-DCAQKATOSA-N Lys-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)N JYVCOTWSRGFABJ-DCAQKATOSA-N 0.000 description 1
• LUAJJLPHUXPQLH-KKUMJFAQSA-N Lys-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)N LUAJJLPHUXPQLH-KKUMJFAQSA-N 0.000 description 1
• LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 1
• CRIODIGWCUPXKU-AVGNSLFASA-N Lys-Pro-Met Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(O)=O CRIODIGWCUPXKU-AVGNSLFASA-N 0.000 description 1
• YSZNURNVYFUEHC-BQBZGAKWSA-N Lys-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YSZNURNVYFUEHC-BQBZGAKWSA-N 0.000 description 1
• VHTOGMKQXXJOHG-RHYQMDGZSA-N Lys-Thr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O VHTOGMKQXXJOHG-RHYQMDGZSA-N 0.000 description 1
• IEIHKHYMBIYQTH-YESZJQIVSA-N Lys-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCCN)N)C(=O)O IEIHKHYMBIYQTH-YESZJQIVSA-N 0.000 description 1
• 101150048453 MSTN gene Proteins 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• IHITVQKJXQQGLJ-LPEHRKFASA-N Met-Asn-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N IHITVQKJXQQGLJ-LPEHRKFASA-N 0.000 description 1
• XKJUFUPCHARJKX-UWVGGRQHSA-N Met-Gly-His Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 XKJUFUPCHARJKX-UWVGGRQHSA-N 0.000 description 1
• YLBUMXYVQCHBPR-ULQDDVLXSA-N Met-Leu-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YLBUMXYVQCHBPR-ULQDDVLXSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
• 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
• 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101100000881 Mus musculus Acta1 gene Proteins 0.000 description 1
• 108010074084 Muscle Proteins Proteins 0.000 description 1
• 102000008934 Muscle Proteins Human genes 0.000 description 1
• 208000029578 Muscle disease Diseases 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 108700001591 MyoD Proteins 0.000 description 1
• 108010056785 Myogenin Proteins 0.000 description 1
• 102000004364 Myogenin Human genes 0.000 description 1
• 206010068871 Myotonic dystrophy Diseases 0.000 description 1
• YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
• SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
• KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
• BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
• 102000005348 Neuraminidase Human genes 0.000 description 1
• 108010006232 Neuraminidase Proteins 0.000 description 1
• 241001028048 Nicola Species 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000017787 Paraneoplastic neurologic syndrome Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 241000196459 Perdix dauurica Species 0.000 description 1
• APJPXSFJBMMOLW-KBPBESRZSA-N Phe-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 APJPXSFJBMMOLW-KBPBESRZSA-N 0.000 description 1
• KDYPMIZMXDECSU-JYJNAYRXSA-N Phe-Leu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 KDYPMIZMXDECSU-JYJNAYRXSA-N 0.000 description 1
• MMJJFXWMCMJMQA-STQMWFEESA-N Phe-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CC=CC=C1 MMJJFXWMCMJMQA-STQMWFEESA-N 0.000 description 1
• 102100037385 Phosphoglycerate mutase 2 Human genes 0.000 description 1
• 102000009097 Phosphorylases Human genes 0.000 description 1
• 108010073135 Phosphorylases Proteins 0.000 description 1
• 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
• 235000011613 Pinus brutia Nutrition 0.000 description 1
• 241000018646 Pinus brutia Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• DRVIASBABBMZTF-GUBZILKMSA-N Pro-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@@H]1CCCN1 DRVIASBABBMZTF-GUBZILKMSA-N 0.000 description 1
• LXVLKXPFIDDHJG-CIUDSAMLSA-N Pro-Glu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O LXVLKXPFIDDHJG-CIUDSAMLSA-N 0.000 description 1
• VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 1
• BBFRBZYKHIKFBX-GMOBBJLQSA-N Pro-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@@H]1CCCN1 BBFRBZYKHIKFBX-GMOBBJLQSA-N 0.000 description 1
• OOZJHTXCLJUODH-QXEWZRGKSA-N Pro-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 OOZJHTXCLJUODH-QXEWZRGKSA-N 0.000 description 1
• IMNVAOPEMFDAQD-NHCYSSNCSA-N Pro-Val-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IMNVAOPEMFDAQD-NHCYSSNCSA-N 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
• 230000004570 RNA-binding Effects 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 241001334102 Rugopharynx sigma Species 0.000 description 1
• 230000018199 S phase Effects 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
• 241000395036 Scaphochlamys Species 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• RZEQTVHJZCIUBT-WDSKDSINSA-N Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-WDSKDSINSA-N 0.000 description 1
• VBKBDLMWICBSCY-IMJSIDKUSA-N Ser-Asp Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O VBKBDLMWICBSCY-IMJSIDKUSA-N 0.000 description 1
• PPNPDKGQRFSCAC-CIUDSAMLSA-N Ser-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPNPDKGQRFSCAC-CIUDSAMLSA-N 0.000 description 1
• PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
• 206010072170 Skin wound Diseases 0.000 description 1
• 102100027722 Small glutamine-rich tetratricopeptide repeat-containing protein alpha Human genes 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 1
• 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 208000032978 Structural Congenital Myopathies Diseases 0.000 description 1
• 208000002847 Surgical Wound Diseases 0.000 description 1
• UNURFMVMXLENAZ-KJEVXHAQSA-N Thr-Arg-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UNURFMVMXLENAZ-KJEVXHAQSA-N 0.000 description 1
• AYCQVUUPIJHJTA-IXOXFDKPSA-N Thr-His-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O AYCQVUUPIJHJTA-IXOXFDKPSA-N 0.000 description 1
• SIEZEMFJLYRUMK-YTWAJWBKSA-N Thr-Met-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N)O SIEZEMFJLYRUMK-YTWAJWBKSA-N 0.000 description 1
• GFRIEEKFXOVPIR-RHYQMDGZSA-N Thr-Pro-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O GFRIEEKFXOVPIR-RHYQMDGZSA-N 0.000 description 1
• SPIFGZFZMVLPHN-UNQGMJICSA-N Thr-Val-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SPIFGZFZMVLPHN-UNQGMJICSA-N 0.000 description 1
• 102000002262 Thromboplastin Human genes 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• UABYBEBXFFNCIR-YDHLFZDLSA-N Tyr-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UABYBEBXFFNCIR-YDHLFZDLSA-N 0.000 description 1
• QHONGSVIVOFKAC-ULQDDVLXSA-N Tyr-Pro-His Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O QHONGSVIVOFKAC-ULQDDVLXSA-N 0.000 description 1
• 102000018165 U1 Small Nuclear Ribonucleoprotein Human genes 0.000 description 1
• 108010091281 U1 Small Nuclear Ribonucleoprotein Proteins 0.000 description 1
• ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 1
• XQVRMLRMTAGSFJ-QXEWZRGKSA-N Val-Asp-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N XQVRMLRMTAGSFJ-QXEWZRGKSA-N 0.000 description 1
• QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
• RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 1
• DLRZGNXCXUGIDG-KKHAAJSZSA-N Val-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O DLRZGNXCXUGIDG-KKHAAJSZSA-N 0.000 description 1
• 102100036021 WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 Human genes 0.000 description 1
• 101710160038 WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 Proteins 0.000 description 1
• 208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 1
• 210000001766 X chromosome Anatomy 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 108010023079 activin B Proteins 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 230000009815 adipogenic differentiation Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 201000006960 adult spinal muscular atrophy Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 108010005233 alanylglutamic acid Proteins 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
• 108010068380 arginylarginine Proteins 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
• 108010038633 aspartylglutamate Proteins 0.000 description 1
• 108010047857 aspartylglycine Proteins 0.000 description 1
• 206010003549 asthenia Diseases 0.000 description 1
• 230000001746 atrial effect Effects 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 229920000229 biodegradable polyester Polymers 0.000 description 1
• 239000004622 biodegradable polyester Substances 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 150000001615 biotins Chemical class 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000004579 body weight change Effects 0.000 description 1
• 230000037182 bone density Effects 0.000 description 1
• 210000004979 bone marrow derived macrophage Anatomy 0.000 description 1
• 230000018678 bone mineralization Effects 0.000 description 1
• 230000037118 bone strength Effects 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 230000003683 cardiac damage Effects 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 239000005482 chemotactic factor Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229940112822 chewing gum Drugs 0.000 description 1
• 235000015218 chewing gum Nutrition 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 229940126523 co-drug Drugs 0.000 description 1
• 238000011278 co-treatment Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 239000005515 coenzyme Substances 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 201000010897 colon adenocarcinoma Diseases 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000000205 computational method Methods 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 108010016616 cysteinylglycine Proteins 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000005014 ectopic expression Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 210000000630 fibrocyte Anatomy 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 230000004190 glucose uptake Effects 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 201000009339 glycogen storage disease VII Diseases 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 108010089804 glycyl-threonine Proteins 0.000 description 1
• 108010020688 glycylhistidine Proteins 0.000 description 1
• 210000001126 granulation tissue Anatomy 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000005534 hematocrit Methods 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 108010028295 histidylhistidine Proteins 0.000 description 1
• 108010025306 histidylleucine Proteins 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 102000054677 human MSTN Human genes 0.000 description 1
• 102000053563 human MYC Human genes 0.000 description 1
• 210000002758 humerus Anatomy 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• 230000003345 hyperglycaemic effect Effects 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229910001867 inorganic solvent Inorganic materials 0.000 description 1
• 239000003049 inorganic solvent Substances 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 229940029329 intrinsic factor Drugs 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 108010071185 leucyl-alanine Proteins 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 208000019017 loss of appetite Diseases 0.000 description 1
• 235000021266 loss of appetite Nutrition 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 235000013372 meat Nutrition 0.000 description 1
• 230000008384 membrane barrier Effects 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 230000001483 mobilizing effect Effects 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 150000004712 monophosphates Chemical class 0.000 description 1
• 230000003551 muscarinic effect Effects 0.000 description 1
• 210000001665 muscle stem cell Anatomy 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 239000007923 nasal drop Substances 0.000 description 1
• 229940100662 nasal drops Drugs 0.000 description 1
• 210000002850 nasal mucosa Anatomy 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 230000005937 nuclear translocation Effects 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229920000620 organic polymer Polymers 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 125000002524 organometallic group Chemical group 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000004293 potassium hydrogen sulphite Substances 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 201000008752 progressive muscular atrophy Diseases 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035752 proliferative phase Effects 0.000 description 1
• 108010014614 prolyl-glycyl-proline Proteins 0.000 description 1
• 108010025826 prolyl-leucyl-arginine Proteins 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 239000012268 protein inhibitor Substances 0.000 description 1
• 229940121649 protein inhibitor Drugs 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• 230000003716 rejuvenation Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 229920002477 rna polymer Polymers 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
• 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
• 108010026333 seryl-proline Proteins 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 230000025185 skeletal muscle atrophy Effects 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 108010005652 splenotritin Proteins 0.000 description 1
• 230000005477 standard model Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 210000004003 subcutaneous fat Anatomy 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 125000004354 sulfur functional group Chemical group 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 238000012385 systemic delivery Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 239000010409 thin film Substances 0.000 description 1
• 230000035922 thirst Effects 0.000 description 1
• 108010061238 threonyl-glycine Proteins 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
• 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
• 208000005606 type IV spinal muscular atrophy Diseases 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 108010073969 valyllysine Proteins 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1